Systems and methods for producing and delivering ultrasonic therapies for wound treatment and healing

Information

  • Patent Grant
  • 11331520
  • Patent Number
    11,331,520
  • Date Filed
    Friday, October 11, 2019
    4 years ago
  • Date Issued
    Tuesday, May 17, 2022
    2 years ago
Abstract
One embodiment is directed to a non-contact, medical ultrasound therapy system for generating and controlling low frequency ultrasound. The ultrasound therapy system includes a treatment wand including an ultrasonic transducer, a generator unit, and a cable coupling the treatment wand to the generator unit. The generator unit generates electric power output to drive the ultrasonic transducer and includes a digital frequency generator, wherein the generator unit digitally controls energy output at resonance frequency of the ultrasonic transducer.
Description
TECHNICAL FIELD

Embodiments relate generally to ultrasound therapy systems and methods and more particularly to a non-contact, low-frequency, highly efficient ultrasound therapy system that delivers ultrasonic therapy treatments via a mist to a patient wound to promote wound healing.


BACKGROUND

Use of ultrasonic waves to promote healing of wounds has become more common in recent years as its benefits are better understood and this type of therapy becomes more widely utilized. In general, ultrasonic waves have been used in medical applications for a long time, including diagnostics, therapy, and industrial applications.


A number of innovative ultrasound therapy systems and devices have previously been developed including non-contact, ultrasound mist therapy devices by the assignee of the current application, Celleration, Inc. These systems and devices have been widely used for medical treatments in medical facilities around the world. See, for example, co-owned U.S. Pat. No. 6,569,099, entitled ULTRASONIC METHOD AND DEVICE FOR WOUND TREATMENT, which is incorporated herein by reference in its entirety. Unlike most conventional wound therapies that are limited to treatment of the wound surface, Celleration, Inc., developed therapies in which ultrasound energy and atomized normal saline solutions were used to stimulate the cells within and below the wound bed to aid in the healing process.


Although these ultrasound therapies have been effective, devices, systems and methods providing improved ultrasonic therapies that are more accessible, safer to administer to patients, and more efficient in delivery of ultrasound energy have been widely desired.


SUMMARY

Embodiments relate to non-contact, low-frequency, highly efficient ultrasound therapy devices, systems and methods that deliver ultrasonic therapy treatments via a mist to a patient wound to promote wound healing. One embodiment is directed to a non-contact, medical ultrasound therapy system for generating and controlling low frequency ultrasound. The ultrasound therapy system includes a treatment wand including an ultrasonic transducer, a generator unit, and a cable coupling the treatment wand to the generator unit. The generator unit generates electric power output to drive the ultrasonic transducer and includes a digital frequency generator, wherein the generator unit digitally controls energy output at resonance frequency of the ultrasonic transducer.


Another embodiment is directed to a highly efficient ultrasonic generator unit. The ultrasonic generator unit includes an ultrasonic driver with digital controls to maintain system displacement at resonance frequency of a transducer coupled to the ultrasonic generator unit. The ultrasonic driver in this embodiment includes a microprocessor, a digital frequency generator, and a phase detector.


A further embodiment is directed to an ultrasonic system. The ultrasonic system includes a user interface controlled by a first microprocessor, a treatment device including an ultrasonic transducer, and a generator unit including an ultrasonic driver controlled by a second microprocessor. In this embodiment both the first microprocessor and the second microprocessor are configured to individually suspend operation of the ultrasonic system in fault condition situations.


A further embodiment is directed to a method for digitally generating and controlling low frequency ultrasound used in a non-contact medical ultrasound therapy system. The method includes performing a power on self-test to an ultrasonic therapy system that includes a treatment wand containing an ultrasonic transducer and a generator unit containing an ultrasonic driver. The method further includes performing a frequency sweep using a sine wave to determine a resonance frequency of the ultrasonic transducer by evaluating and looking for a relative minimum impedance of the ultrasonic transducer. The method further includes adjusting the digital frequency generator output frequency based on voltage vs. current phase angle so that a frequency lockup is maintained at the resonance frequency, and monitoring voltage and phase detection circuits of the ultrasonic therapy system for phase difference.





BRIEF DESCRIPTION OF THE DRAWINGS

The invention may be more completely understood in consideration of the following detailed description of various embodiments of the invention in connection with the accompanying drawings, in which:



FIG. 1 is an ultrasound device of a system providing non-contact therapy to patient wounds via a low frequency ultrasound mist, according to an embodiment.



FIG. 2 is a diagram of an ultrasound therapy system, according to an embodiment.



FIG. 3 is a diagram of an ultrasound therapy system, according to an embodiment.



FIG. 4 is a diagram of an ultrasound device of a system providing for non-contact therapy to patient wounds via a low frequency ultrasound mist, according to an embodiment.



FIG. 5 is a diagram of the interaction of the DDS (Direct Digital Synthesis) feature and microprocessor that provides digital frequency generation, according to an embodiment.



FIG. 6 is a diagram of the frequency control loop of the system, according to an embodiment.



FIG. 7 is a diagram of the constant current control loop of the system, according to an embodiment.



FIG. 8 is a graph of an example of impedance versus frequency, in an ultrasonic transducer device, according to an embodiment.



FIGS. 9a-9g show a diagram of the operation of the ultrasonic therapy system, according to an embodiment.





DETAILED DESCRIPTION OF THE DRAWINGS

Various embodiments may be embodied in other specific forms without departing from the essential attributes thereof, therefore, the illustrated embodiments should be considered in all respects as illustrative and not restrictive.


A need for a more accessible and safer ultrasonic therapy device and system for patients to use has been recognized in this disclosure. Further, many of the substantial technical obstacles to providing such a device based on the requirements of conventional ultrasound therapy devices are recognized and overcome by this disclosure. Specifically, making devices more readily accessible to additional patient populations has been a significant problem due to the very high voltage necessary to operate conventional devices. For example, some conventional ultrasound therapy devices have operated at about 700 Volts (V) peak-to-peak and 7 Watts (W) of energy. This has necessitated qualified oversight of therapy provision, as allowing patients to operate such a high voltage machine on their own might otherwise present a significant safety risk. Further, the energy requirements of conventional devices have made the possibility of a portable battery powered device, which could be used in a homecare environment, unfeasible. Ultrasound therapy systems described herein, however, overcome many or all of the technological obstacles of the past and provide a lower-power, safer, more efficient, and more accessible ultrasound therapy system. In embodiments, an ultrasound therapy system can be monitored and controlled to operate at or near resonant frequency (Fr), which can be more efficient that operating at or near anti-resonant frequency because it requires less voltage and is more efficient. Even battery powered systems are possible in certain embodiments. Accordingly, designs for new medical ultrasound devices, systems and methods incorporating various features, concepts and improvements, are described in the following detailed description.



FIG. 1 shows an example of a medical ultrasound device 20 of an ultrasound therapy system 10 (refer, e.g., to FIG. 2) for delivering non-contact ultrasound therapies to patient wounds via a low-frequency ultrasound mist. Medical ultrasound device 20 comprises both a console/generator unit 30 for generating power and a treatment wand 40 for administering therapies. In general, generator unit 30 supplies power to an ultrasonic transducer within the treatment wand 40. Treatment wand 40 is ergonomically designed and can be generally pistol-shaped such that it may be conveniently positioned by a user to direct ultrasonic energy to a treatment area via atomized saline mist emitted from the end of treatment wand 40. Treatment wand 40 also can be balanced, such as in its physical design and weight distribution, to further improve and enhance ergonomics and usability. Generator unit 30 further comprises an external pump 50 which pumps saline or other fluid through a tube (not shown) attached to the end of treatment wand 40. Pump 50 depicted in FIG. 1 is a peristaltic pump but can comprise another suitable pump type or mechanism in other embodiments.



FIGS. 2 and 3 show high-level block diagrams of components of ultrasound therapy system 10. In general, as depicted in FIG. 2, system 10 comprises generator unit 30; treatment wand 40; fluid management pump 50; an ultrasonic driver 60; an ultrasonic transducer 70; and an applicator 80.


Generator unit 30 and treatment wand 40 are connected by a cable 90. Ultrasonic driver 60 comprises hardware mounted inside generator unit 30. A basic function of the ultrasonic driver 60 is to generate electric power output to drive ultrasonic transducer 70. Ultrasonic transducer 70 includes an acoustic horn 100 and related assembly mounted inside treatment wand 40. Ultrasonic transducer 70 converts and transfers input electrical power into vibrational mechanical (ultrasonic) energy that will be delivered to the treatment area (i.e. to a patient wound area via atomized saline). Treatment wand 40 contains the system's user interface 110 and controls for parameters of the treatment, though in other embodiments an additional or alternative user interface can be incorporated in generator unit 30. Treatment wand 40 is configured to appropriately position and hold applicator 80 relative to acoustic horn 100 for proper delivery of fluid during operation. The configuration also provides appropriate atomization of saline fluid and delivery of the resulting mist and ultrasound energy to a wound treatment area.


Fluid management pump 50 provides a fixed flow rate of saline or other fluid (e.g., about 0.9% normal saline in one embodiment) via a tube 120 to the distal tip 140 of ultrasonic transducer 70 from a saline bag 130 or other source, as appropriate. The saline fluid is delivered to the radial surface of transducer horn near its tip 140. The saline fluid is dispensed through an orifice on a superior surface of the horn 100, and a portion of the saline is displaced forward to the face of horn 100 and atomized by horn 100 when it is energized and operating. The remaining volume of fluid is fed to an inferior surface of ultrasonic transducer 70 via gravity and capillary action. When a sufficient volume of saline is accumulated, transducer tip 140 atomizes the saline into a plume. The atomized saline spray plume emanates from two points on the ultrasonic transducer 70, i.e., generally at the 12 o'clock and 6 o'clock positions given normal positioning of treatment wand 40 in operation, forming intersecting spray paths at approximately 5 mm from the front face of ultrasonic transducer 70 in some embodiments. In other embodiments, treatment wand 40, transducer 70, horn 100, tip 140 and/or other components can be designed to provide a differently sized or configured spray plume and paths.



FIG. 4 is a block diagram of a more detailed schematic of generator unit 30 and treatment wand 40 of ultrasound device 20. As can be understood from the following description, parameter control of voltage, current, duty cycle and phase angle is enabled, in some embodiments.


Treatment wand 40 houses ultrasonic transducer 70 and includes a microprocessor 200, various interface and sensing components, and an OLED display 206. Treatment wand 40 is pistol-shaped in embodiments to provide an improved ergonomic operator design, though other configurations can be implemented as may be advantageous in some applications. Treatment wand 40 comprises an acoustic horn assembly (e.g., piezo elements, back mass, horn and booster), ultrasonic transducer 70, microprocessor (MCU2) 200, user control key pad 202 and trigger 204, and an LCD screen display 206 that displays operational information and enables control and programming of the treatment therapy (see, e.g., FIG. 1). Treatment wand 40 also includes an RFID transceiver 208 in some embodiments, and RFID transceiver 208 can be used to identify applicator 80. This feature can be used to ensure that there is only a single use of a particular applicator 80 and to thereby deter unwanted reuse across multiple patients and/or treatments. Treatment wand 40 connects to generator unit 30 through cable 90. Cable 90 includes ultrasonic driver output power, communication components (such as those compatible with RS485, RS422 and/or other protocols) and power components (such as +5V and ground) in an embodiment, though other power and/or communications features can be implemented or facilitated by cable 90 in other embodiments. In one embodiment, 3.3V and 12.9V power can be generated from the 4.5V power provided by generator unit 30 for the electronics in the treatment wand 40. These example power characteristics can vary and are merely examples of one embodiment.


User interface 110 on treatment wand 40 includes key pad 202, trigger 204, and screen display 206. In some embodiments, display 206 can be a full-color OLED display, and key pad 202 can be a four button display, as shown in FIG. 1. The operator can configure and control device and system operation via key pad 202 and initiate the delivery of therapies by depressing a trigger switch 204.


Microprocessor 200 that controls user input requirements can also measure the internal temperature of treatment wand 40, or of transducer 70 or horn 100 more specifically, from ultrasonic transducer sensor 210 and treatment wand sensor 212. Microprocessor 200 also sends read/write information to applicator 80. Microprocessor 200 communicates with generator unit 30 via a communications protocol transceiver 214 (such as one compatible with RS485, RS422 and/or other protocols) and writes information to memory 216, which can be EEPROM, serial flash, or some other suitable memory. This information is stored and can be retrieved for understanding the use and performance of the system. Accordingly, greater detail can be given on data stored, how much, how long and how retrieved (USB upload/download by the user, service or other).


RFID transceiver 208 of treatment wand 40 can be used to communicate with an RFID tag (not shown) for applicator detection, as previously mentioned. The RFID tag can be located on applicator 80, and microprocessor 200 in treatment wand 40 can serve as an RFID reader and writer of the signals received via RFID transceiver 208. Specifically, an RFID controller can be used in treatment wand 40 for a Read/Write RF tag on applicator 80. In each new treatment, system 10 will require a new applicator 80. The RFID controller can read the ID tag of applicator 80 to identify if that particular applicator 80 is new or used. After a particular applicator 80 is used for a specified period of time, the RFID controller can write the information to an ID tag to identify that applicator 80 has been used to avoid reuse.


Microprocessor 200 of treatment wand 40, or another component of system 10, can be used to control input and output functions and perform control loops and calculations. Features of microprocessor 200 or another microprocessor or component of system 10 in some embodiments can include: an 80 MHz maximum frequency; 1.56 DMIPS/MHz (Dhrystone 2.1) performance; an operating voltage range of 2.3V to 3.6V; a 512K flash memory (plus an additional 12 KB of Boot Flash); a 128K SRAM memory; a USB 2.0-compliant full-speed device and On-The-Go (OTG) controller; up to 16-channel, 10-bit Analog-to-Digital Converter; six UART modules with RS-232, RS-485 and LIN support; and up to four SPI modules. These features are merely examples of one embodiment and can vary in other embodiments.


Ultrasonic transducer 70 generally comprises a piezoelectric ceramic element and metal horn 100 mounted in a sealed housing. The ultrasonic transducer input can be an AC voltage or AC current, or an AC voltage that results in a current, and the waveform can be a square form or sine form. The ultrasonic transducer output is mechanical vibration of the tip of transducer 70. The amount of energy output depends on tip 70 displacement, frequency, size and driver load (e.g., air or liquid mist). The ratio of output to input energy is referred to as the electromechanical coupling factor. There are many variables that affect coupling factor, including frequency. In theory, it can be advantageous to operate an ultrasonic transducer (sometimes referred to as UST) by keeping the operating frequency in the resonant frequency (Fr) or anti-resonance frequency (Fa) region. At Fr, the electrical power factor is 1, while near or approaching Fr the power factor only approaches 1. However, due to the related, very unique impedance-frequency characteristics of transducers, which can vary from transducer to transducer, drive circuit design is very difficult. In previously designed ultrasonic drivers, Phase Loop Lock (PLL) techniques were widely used. Because of the nature of analog performance, keeping a highly accurate and stable frequency output was very difficult. In theory, an ultrasonic transducer that operates at Fr or Fa has a high efficiency output. In practice, operating a UST at Fr or Fa can be difficult or impossible with PLL technology. This is why most ultrasonic drivers with a PLL design only can operate in Fr or Fa regions rather than at Fr or Fa points, and the operational phase typically may be more than 50 degrees. For most systems with rapidly changing load impedance, operation at frequencies close to Fa or Fr will cause the system to be unstable. Alternatively, a system can be kept stable by setting the operation frequency lower than Fr or higher than Fa points, so long as the frequency does not drift to a resonant point. In embodiments discussed herein, however, the ultrasonic driver can be monitored and controlled to operate at or very near Fr, a significant advantage over conventional systems.


In embodiments, Fr and Fa can be equated or analogized with serial and parallel, respectively, resonance frequencies. This is shown in Table 1:










TABLE 1








V/I Phase = 0 degrees









Defined
Impedance = Minimum
Impedance = Maximum





Mechanical
Resonance
Anti-resonance



frequency (Fr)
frequency (Fa)


Electrical
Serial resonance frequency
Parallel resonance frequency



V/I phase = 0 degrees
V/I phase = 0 degrees


Ultrasound
ZFr = minimum



system 10
and




Phase = 0 degrees




Frequency = 39 kHz~41 kHz









Ultrasonic transducer 70 is operated at relatively large displacements and a low load variation, thereby reducing loading effects and electrical impedance. Accordingly, ultrasonic medical applications can use a constant current control algorithm to achieve one or more of the following performance advantages: increased electrical safety due to lower operating voltage; lower operating voltage by running at Fr; proportional current to maximum tip velocity (displacement if frequency is held constant); tip displacement proportional to current; and the capability to limit excessive power surges by setting the voltage rail to an appropriate value, among others.


Generator unit 30 includes a power entry module and AC/DC power supply 300 as well as an ultrasonic driver 60. Delivery pump 50 is mounted on generator unit 30 and is controlled by a pump driver located on ultrasonic driver 60. Communications ports 302, 304, and 306 are also located on the generator unit 30, though the number and arrangement of communications ports can vary from those depicted. For example, in other embodiments more or fewer ports are provided, and one or more of the ports can comprise a wireless communications port (e.g., infrared, RF, BLUETOOTH, WIFI or some other wireless technology). These ports provide an information exchange between generator unit 30 and treatment wand 40 as well as information exchange between device 20 and user.


With respect to the Power Entry Module & AC/DC Power Input, in some embodiments the local AC MAINS is connected to an appliance inlet with a hospital grade detachable power cord. In some embodiments, different types of power cords can be used: 15 A with a 125V rate, or 10 A with a 250V rate. In some embodiments, the appliance inlet is a power entry module listed for medical applications with an 10 A current rating, 120/250 VAC voltage input, MAINS switch, integral fuse holder (2¼×1¼″/5×20 mm fuses), EMC line filter for medical applications, and is mounted on the rear panel of the chassis. Although not depicted in the figures, embodiments are contemplated that use battery power as the power source in the system's design. The battery would be located within generator 30 in various embodiments. Battery power is made possible due to the extremely efficient design discussed herein.


In some embodiments, system 10 can have a universal AC power input capability accepting a range of power input from 90V to 265 VAC. The local AC MAINS are connected to an appliance inlet component (IEC 320 C14) with a hospital grade detachable power cord. The appliance inlet is a power entry module listed for medical applications with an 115V/230V voltage input, MAINS switch, integral fuse holder (2-5×20 mm fuses), and an EMC line filter for medical applications that is mounted on the rear panel of the chassis. The MAINS switch output is connected to two AC/DC switching power modules. The two AC/DC (24V output) switching power supply modules provide +/−24V power to class-AB type amplifier use. All DC power sources +5V, +4.5V, −4.5V and 3.3V can be generated from a +24 VDC power source via DC/DC converter. The +5 VDC will provide 5V power to treatment wand 40 through the detached cable and medical grade connector 90. While class-AB amplifiers are mentioned in examples here and elsewhere, in embodiments class-D or other amplifiers also can be used.


In some embodiments, two identical AC/DC (24V output) switching power supply modules are serially connected together to provide +/−24V power to class-AB type amplifier use. The power supply can be medical grade, Class II, BF rated with 45 W output with conventional cooling. A dual color (Red/Green) LED 308 can be mounted at the front of generator unit 30. The green color indicates normal power on without errors, and the red color indicates a system error or failure. Error detail information can also display on the interface display screen 206 of treatment wand 40.


In some embodiments, there is a plurality of, such as three, communication ports in the on generator 30. The first port is a communication port 302 (such as one compatible with RS485, RS422 and/or other protocols), with 5V power and UST outputs. This port 302 is connected to treatment wand 40 through cable 90. Port 302 can be configured for full duplex communications in both directions at the same time. This port 302 can handle information exchange between generator unit 30 and treatment wand 40. In operation, both sets of microcontrollers 200 and 316 can check each other to ensure none has failed to operate through this port 302. The second port can be a USB-2 type A port, referred to herein as port 304. It can be designed for user download of information stored at the memory 310, which can comprise EEPROM, serial flash, internal non-volatile, or other suitable memory, by using a flash key or other device. This port 304 can be used for uploading software from flash key device. A third port can be an RS232-3.3V serial port, referred to herein as port 306. Port 306 can be designed for use with a PC, so the PC can communicate to the system 10 for download, upload, system debug and calibration. Also included in generator unit 30 and connected to the microcontroller are RTC at numeral 305, an audible signal generator 307 and generator temperature sensor 309, though in embodiments one or more of these features can be omitted or relocated. For example, in one embodiment audible signal generator 307 can be located in treatment wand 40 instead of or in addition to being in generator unit 30.


A microcontroller controlled pump delivery system 312 can be used for fluid delivery. Delivery system 312 comprises a pump 50 and pump driver with controls 314 for pump speed and pump door monitoring and can deliver fluid, such as saline, through a tube 120 and applicator 80 to the tip of ultrasonic transducer 70. Microcontroller (MCU1) 316 of generator unit 30 can control peristaltic pump speed to control saline flow rate for a fixed tubing size. Pump delivery system 312 generally operates at constant flow rate for all operating conditions. A cooling fan 317 is mounted in the back of generator unit 30. It is controlled by microcontroller 316 of ultrasonic driver 60.


Ultrasonic driver 60 includes a microprocessor 316 that controls, measures and monitors the drive electronics and communicates with the hardware and software of the treatment wand 40. In some embodiments, ultrasonic driver 60 includes a microprocessor 316 (such as Microchip Technology Inc. PIC32) with an 80 MHz clock and 1.56 DMIPS/MHz performance, though some other suitable microprocessor can be used in other embodiments. The drive electronics contain a digital frequency generator (DDS) 318, AC amplifier 320 and voltage and current peak detection circuits 322 and 324. Digital frequency generator 318 generates accurate frequencies set by microprocessor 316 to AC amplifier 320 that are output to ultrasonic transducer 70. In some embodiments, AC amplifier 320 can be coupled to impedance matching circuitry 326, though in other embodiments this circuitry 326 can be omitted or implemented in software or firmware rather than hardware. Voltage and current peak detection circuits 322 and 324 continually monitor the signal peaks with phase difference sensed at 328. In some embodiments, internal or external timers can be used to monitor phase difference or in the monitoring of phase difference. In operation, microprocessor 316 can adjust the digital frequency generator output frequency based on voltage vs. current phase angle so that the frequency is locked at the resonance frequency Fr of ultrasonic transducer 70. The resonance frequency Fr is not a fixed frequency, however, as it can drift with temperature and other changes. This is discussed herein below in additional detail.


Ultrasonic driver 60 includes a digital frequency generator 318, a resonance frequency control loop 400, and an output current control loop 500. Microcontroller 316 can be of sufficiently high speed so as to handle all input measurements and output settings, especially for phase comparison of cycle by cycle frequency adjustment in real time. Ultrasonic driver 60 generates electrical output with an ultrasonic frequency and a required power.


At Fr and Fa, the impedance phase is 0 degrees, which means that ultrasonic transducer 70 can achieve the highest power efficiency at those points. Accordingly, it is recognized that keeping the output frequency close to Fr or Fa would be desirable, if possible. However, it is very difficult for any control systems to operate at Fr and Fa, as at those points any small increase or decrease of frequency will cause a large impedance increase or decrease. Accordingly, most ultrasonic drivers either operate at frequencies higher than Fa or lower than Fr because frequencies are relatively stable when they are farther from Fr or Fa.


For example, some conventional systems have been designed to operate in the Fa region. These designs were relatively stable and delivered effective treatment, but output power efficiency was very low and a very high operating voltage was required. Accordingly, in order to meet regulatory safety requirements, wires with high isolation and earth protection were required, adding cost and restricted user ergonomics due to a stiffer and heavier cable.


An example comparing the voltage required by a past device operating at Fa compared to an embodiment of the currently disclosed system, operating at Fr, is set forth below:


A conventional ultrasonic transducer was operated at, or above, anti-resonance, which is approximately 1 KΩ˜8 KΩ impedance. To deliver the required power to the transducer the driver must output very high voltage (300V) to the transducer. The power calculation is:

P=I2Z*Cos φ  Equation 1

    • P: input power of transducer
    • I: input current
    • Z: transducer impedance in Ohm
    • φ: voltage vs. current phase angle (−90°˜+90°)


      If the transducer requires 7 W power, φ=85°, Z=1500Ω, from Equation 1 the current will be:






I
=



P

Z
*
Cos





φ


2

=




7





W


1500

Ω
*

Cos


(

85

°

)




2

=

230





mA








Accordingly, a power supply voltage would be: (230 mA*1500Ω)=345V.


An embodiment of system 10, in contrast, operates at Fr with constant current output control. Its impedance is about 25˜80Ω and voltage vs. current phase angle close to 0 degrees. The power efficiency is almost 100%. An example with Fr impedance is 50Ω.


If the transducer requires 7 W power, φ=0°, Z=50Ω, the current will be:






I
=



P

Z
*
Cos





φ


2

=




7





W


50

Ω
*

Cos


(

0

°

)




2

=

370





mA








and the power supply voltage will be: 370 mA*50Ω=18.7V


Accordingly, embodiments of system 10, with a low voltage operation condition, can be much more efficient and safer than conventional designs. Any voltage surges resulting when transducer impedance is increased can be limited by setting the voltage rail to an appropriate value.


Microcontroller 316 of the ultrasonic driver controls all input and output functions and performs all control loops, calculations. Embodiments of microcontroller 316 can include one or more of the following: a 80 MHz maximum frequency; 1.56 DMIPS/MHz (Dhrystone 2.1) performance; an operating voltage range of 2.3V to 3.6V; a 512K flash memory (plus an additional 12 KB of Boot Flash); a 128K SRAM memory; USB 2.0-compliant full-speed device and On-The-Go (OTG) controller; up to 16-channel, 10-bit Analog-to-Digital Converter; six UART modules with RS-232, RS-485 and LIN support; and up to four SPI modules. These characteristics are merely examples and can vary in other embodiments.


The ultrasonic frequency generator is a digital frequency generator 318 that provides numerous advantages over conventional designs. In some conventional designs, PLL technology was used with or comprises part of a voltage control oscillator (VCO) for generating a fixed ultrasonic frequency. However, this produced an output frequency that is low resolution and not flexible for wide frequency range applications without hardware changes. Further, the frequency stability was imprecise since the VCO is affected by temperature, noise and power ripple.


In the current ultrasonic therapy system 10, a Direct Digital Synthesis programmable frequency generator (DDS) is used as part of the frequency generator 318. Because a DDS is digitally programmable, the output frequency can be easily adjusted over a wide range. DDS permits simple adjustments of frequency in real time to locate resonance frequencies or compensate for temperature drift. The output frequency can be monitored and adjusted based on phase difference measurements in embodiments, and can be continually adjusted by microcontroller 316 at real time speed. Advantages of using DDS to generate frequency include: digitally controlled sub-Hertz frequency-tuning resulting in sub-degree phase-tuning capability; extremely fast speed in tuning output frequency (or phase); and phase-continuous frequency hops with no overshoot/undershoot or analog-related loop setting-time anomalies, among others. In embodiments, a sine-wave output can be generated by the ultrasonic transducer, which can provide cleaner signals to sensing circuitry. Additionally, because the voltage and current maintain a very close semblance of a sine wave, peak sensing can be used without requiring more elaborate true Root Mean Square (RMS) conversion.


The digital architecture of DDS eliminates the need for the manual tuning and tweaking related to components aging and temperature drift in analog synthesizer solutions, and the digital control interface of the DDS architecture facilitates an environment where systems can be remotely controlled and optimized with high resolution under processor control. FIG. 5 shows the system's digital frequency generation using microcontroller 316 and DDS 318. Specifically, frequency set 370 and amplitude set 372 are received by DDS 318 which generates an output frequency 374 (fout).



FIG. 6 sets forth the frequency control loop 400 for system 10. Frequency control loop 400 includes a digital frequency generator (DDS) 318, D/A converter 378, phase detector 380 and microprocessor 316. The drive electronics utilize the digital frequency generator 318, AC amplifier 320 and voltage and current peak detection circuits 322 and 324. Digital frequency generator 318 generates a high accuracy and precision frequency signal, set by the microprocessor 316, to AC amplifier 320 that outputs across a transducer load 382 to ultrasonic transducer 70. At start-up, system 10 performs a Power On Self-Test (POST) and communicates with ultrasonic transducer 70 to gather information on characteristics of ultrasonic transducer 70 and determine that treatment wand 40 is functioning properly.


Specifically, when initially energized, microprocessor 316 can be programmed to perform a frequency sweep using a sine wave to determine the resonant frequency by evaluating and looking for a relative minimum impedance of ultrasonic transducer 70. The sweep is confined to a smaller defined interval based on the information embedded in treatment wand 40 regarding the operating characteristics of ultrasonic transducer 70. This includes the information stored about ultrasonic transducer 70 at the time of manufacture or otherwise programmed or updated. During the system start, digital frequency generator 318 can scan frequencies from a start frequency (min 20 KHz, adjustable) to an end frequency (max 50 KHz, adjustable) to find the resonance frequency (Fr). Microprocessor 316 can adjust the digital frequency generator output frequency based on voltage vs. current phase angle so that the frequency lockup is maintained at the resonance frequency of ultrasonic transducer 70 (i.e., at a 0° phase angle). Because the frequencies continually shift due to temperature change and other factors, the phase of output voltage and current will change as well. The voltage vs. current phase detection circuits are continually monitored for the phase difference and the frequency adjusted accordingly. Resonance frequency is not a fixed frequency. This is due to heating and other factors causing a slight drift change with temperature. Specifically, increased temperature can cause decreased resonant frequency.


In order to keep output frequency lockup at resonance frequency, frequency control loop 400 can monitoring output voltage vs. current phase angle in real time and continually adjust operating frequency to match the current resonance frequency. In some embodiments, microprocessor 316 can maintain Δφ (as illustrated at 390) to less than about 0.1 degree inaccuracy and provide sufficient capabilities to achieve accuracy of about 0.1 Hz or better. In some embodiments, resonance frequency is digitally controlled to better than about 0.5 Hz while maintaining constant energy output.



FIG. 7 sets forth output current control loop 500 for system 10. Output current control loop 500 is designed to provide a constant current output. Since the transducer output displacement is a function of transducer drive current, the control output current (not voltage) will control output displacement. Displacement, of a given tip area, determines the amount of ultrasound energy delivered/output. Microprocessor 316 monitors the output current via a sensing resistor then adjusts the digital frequency generator 318 output signal level to maintain constant current output thus maintaining a constant output displacement from the tip of the horn. Current sensing circuit 322 can sense peak current, and in some embodiments, such as for data logging format output or other purposes, convert peak value to an RMS value. Any waveform distortion can cause converter errors, causing current control errors and ultimately displacement errors. To avoid this situation, embodiments of the system can use RMS sensing technology to reduce the errors. This can be implemented if the waveform has considerable distortion, for example.


In system 10, the digital frequency generator 318 can be used to allow for selection and use of different frequencies via software implementation. Configurations having operating frequencies ranging from about 20 kHz to about 50 kHz are possible. Digital frequency generator 318 is digitally programmable. Accordingly, the phase and frequency of a waveform can be easily adjusted without the need to change hardware (frequency generating components), unlike VCO or PLL based generators, as would normally be required to change when using traditional analog-programmed waveform generators. Digital frequency generator 318 permits simple adjustments of frequency in real time to locate resonance frequencies or compensate for temperature drift or other deviations in the resonant frequency. The output frequency can be monitored via phase difference measurements and continually adjusted by microcontroller 316 at real time speed.


There are many advantages to using digital frequency generator 318 to generate frequency. For example, this provides a digitally controlled, 0.01-Hertz frequency-tuning and sub-degree phase-tuning capability as well as extremely fast speed in tuning output frequency (or phase). The digital frequency generator 318 also provides phase-continuous frequency change with no overshoot/undershoot or analog-related loop setting-time anomalies. The digital architecture of the digital frequency generator 318 eliminates the need for the manual tuning and tweaking related to components aging and temperature drift in analog synthesizer solutions, and the digital control interface of the digital frequency generator architecture facilitates an environment where systems can be remotely controlled and optimized with high resolution under processor control.


In this system, ultrasonic driver 60 outputs a sine waveform through a class AB power amplifier 320. It can operate at frequency from 20 KHz to 50 KHz, constant current mode. The ultrasonic driver 60 outputs current from 0 to 0.65 A, voltage from 0 to 30 Vrms, Max power to 19.5 W, in embodiments, though these values and ranges can vary in other embodiments. The ultrasonic driver output can scan resonance frequencies from the 20 KHz to 50 KHz range, detect minimum impedance (0° degree phase angle of voltage vs. current), and then lock operational frequency to resonance frequency of the ultrasonic transducer 70 at a ±0.5 Hz accuracy level. Parameters may vary in various embodiments. In certain embodiments, the drive voltage requirements are less than 50 Vrms for the system.


The technology of system 10 is unique in that it sees an essentially constant load. The no-load condition is similar to the operational load. Being a non-contact treatment and dispensing only a small amount of fluid onto the horn does not create a significant variation in the load/output, allowing the system to be run at resonance (Fr). Running and controlling the system at Fr allows improved efficiency, as previously discussed. Typical ultrasound applications such as welding, mixing, cutting, and cleaning have significant variation in the load, e.g., going from a no-load to full load condition. The variation makes control of the output very difficult and requires greater power at the cost of efficiency.



FIG. 8 is a graph that helps to illustrate advantages of using system 10's ultrasonic driver based on the impedance and frequency characteristics of ultrasonic transducer 70. Specifically, the dramatic change in impedance magnitude 602 and phase 604 is seen for changes in frequency 606 for even small deviations from the resonance frequency 608 and anti-resonance frequency 610. Ultrasonic transducer 70 is a component that converts electrical energy to mechanical energy. Its impedance and frequency characteristics create significant drive circuit design challenges, especially if trying to optimize for low power input and accuracy. Traditional ultrasonic driver designs typically use Phase Loop Lock (PLL) frequency control technology. However, analog system performance generally does not allow for accuracy and stable frequency output. Accordingly, this can make it difficult to control the system precisely with analog systems. In theory, an ultrasonic transducer operating at resonance frequency Fr or anti-resonance Fa frequency has a high efficiency output. In practice, when ultrasonic transducers operate at resonance frequency or anti-resonance frequency, it is almost impossible using PLL technology to maintain elegant control. Typical ultrasonic drivers utilize an analog PLL based design for control. The PLL based designs operate close to resonance frequency or anti-resonance frequency points, but due to their inherent inaccuracy, these often operate at some phase angle away from Fr or Fa leading to inefficiencies.


In system 10, a constant current control algorithm can be used. It can operate at resonance frequency, rather than just close to resonant frequency. The difference between anti-resonance and resonance is that at anti-resonance the system can operate with high impedance and at resonance with lowest impedance. The high impedance can be in the range of about 5 KΩ to about 50 KΩ, and low impedance can be in a range of about 20Ω to about 100Ω in certain embodiments, for example.


Since ultrasonic transducer 70 is operated with relatively large displacements and a low load variation, there is a significant reduction in loading effects and electrical impedance variation. Many ultrasonic medical applications use a constant current control algorithm because of the following performance advantages: electrical safety (such as due to a lower operating voltage); current that is proportional to frequency and/or maximum tip velocity (displacement if frequency is held constant); fewer excessive power surges (by setting and maintaining the voltage rail to an appropriate value); and the ability to monitor and control displacement of the tip.


Some embodiments of system 10 have three modes of operation: a TREATMENT mode; an INFORMATION mode; and a TERMINAL mode. If the user enters the TREATMENT or normal operating mode upon power up, the user can select the length of time for a treatment and energize the acoustic output to treat a patient. If the INFORMATION mode is entered on power up with a flash key plug to the USB port, user information can be downloaded that has been stored in the memory to flash or new software can be uploaded from the flash key to the system. Finally, a TERMINAL mode can be selected that is an engineering mode for internal device calibration, system characterization, and system evaluation.


System 10 may also save all information of the device hardware and software as well as the user's input and treatments during operation. In some embodiments, system 10 has enough memory storage for all information saved for at least one year of operation. For example, system 10 may implement 2 MB EEPROM and flexible size memory in some embodiments.



FIGS. 9a-g combine to provide a flow diagram operational method 700 of ultrasonic system 10. In various embodiments, one or more tasks or steps can be omitted, or intervening tasks or steps can be carried out in addition those specifically depicted. Operation begins by first powering on the system at 702, followed by conducting a system self-test at 704.



FIG. 9c shows the steps of self-test 704. First, system 10 can verify the integrity of the executable code and verifies RTC at 706. Next, at 708, if the self-test is passed, operation continues on to 714. If the self-test is not passed, an error message is displayed at 710 on display 206 and the system may be shut down at 712. The error message may be used to communicate the issue to customer service.


If 714 is reached (in FIG. 9a), the number of wounds and size of wounds are input. If a new applicator 80 is present at 716, operation proceeds, if not, a new applicator 80 is loaded at 718. Next, at 720, tuning mode commences.



FIG. 9d shows tuning mode 720. First, the tuning mode voltage is set at 722. Next the current loop is set off at 724, followed by a search for the resonance frequency Fr of ultrasonic transducer 70 at 726. If the resonance frequency is found at 728, the system continues on to 738. If the resonance frequency is not found the system will try again for a set number of times at 730. If resonance frequency is not found, after these attempts, an error is displayed on the system display 206 at 734, followed by system shutdown at 736.


If 720 is reached (in FIG. 9a), treatment is started following a successful tuning mode. Next, at 740, the system checks the RFID tag on the applicator 80 for a valid state and to ensure that the treatment has proceeded for less than ninety minutes. If not, treatment is stopped at 742 and a new applicator is loaded at 718 before reengaging the operation at 716. If the RFID tag indicates treatment of less than 90 minutes and a valid state at 740, then operation continues on to pump control at 744.



FIG. 9e shows the pump control 744. First, the system 10 can check that the pump door of the peristaltic pump 50 located on the exterior of the console/generator unit 50 is closed at 746. If not, the display 206 indicates a message to close the pump door at 748. If the pump door is closed, operation continues to 750 where the pump speed is set. The system then can check the pump speed at 752, and the pump speed is set again if necessary, before proceeding on to 754 when the pump control is complete. In some embodiments, checking pump speed and setting or resetting the speed (e.g., one or both of 750, 752) can be omitted.


When 754 is reached (FIG. 9a), the current is set for the ultrasonic transducer 70. Next, the operation frequency is set at 756 and the voltage and current phase is measured at 758. See FIG. 9b. Next, monitoring the system commences at 760.



FIG. 9f shows monitoring the system at 760. First the system monitors: the temperature of the generator unit 30; the temperature of the treatment wand 40; the temperature of the case of the ultrasonic transducer 70; the output voltage of the ultrasonic transducer 70; the current of the pump 50; and the communication between the two microprocessors 200 and 316 (MCU2 and MCU1). Next, error codes are generated and communicated at 764 before returning to 766.


When 766 is reached (FIG. 9b), if the system is not determined to be in order, an error message is communicated on the display 206 at 768 and the system is shut down at 770. If, however, the system is determined to be ok at 766, the system checks to ensure the voltage/current phase angle is 0° at 774. If not, operation reverts to 756 in which the operation frequency is adjusted to so that a voltage/current phase angle of 0° can be achieved. If voltage/current phase angle is set to 0° at 772, the system checks to ensure the current sensed is equivalent to the current that was set for the system at 774. If the current does not match, operation reverts to 754 and the transducer sets the current again before continuing. If the current is appropriate at 774, the system then tests to see if the treatment has timed out at 776. If it has not timed out, operation reverts to 740 and the test of 90 minute RFID time limit is conducted. If treatment has timed out at 776, the treatment is stopped at 778 followed by the option to add a further treatment or additional time at 780. If another treatment or additional time is desired, another treatment is added at 782 and operation reverts to the tuning mode at 720. If no further treatment is desired, information is saved at 784.



FIG. 9g shows saving information 784 in greater detail. First, the system collects device setup information, device operation information, and user treatment information at 786. Next, at 788, information is saved to memory (which can be EEPROM or some other memory type or form, such as serial flash or non-volatile in various embodiments) before continuing to system shutdown at 770.


As understood by the various system checks and protocols in this operational explanation, the operation of the system can be suspended at many points. Advantageously, in certain embodiments, both microprocessor 200 and microprocessor 316 are configured to individually suspend operation of the ultrasonic system in fault condition situations. This arrangement provides enhanced safety not present in other types of designs.


It should also be appreciated that the exemplary embodiment or exemplary embodiments are only examples, and are not intended to limit the scope, applicability, or configuration of the invention in any way. Rather, the foregoing detailed description will provide those skilled in the art with an enabling disclosure for implementing the exemplary embodiment or exemplary embodiments. It should be understood that various changes can be made in the function and arrangement of elements without departing from the scope of the invention as set forth in the appended claims and the legal equivalents thereof.


The embodiments above are intended to be illustrative and not limiting. Additional embodiments are within the claims. Although the present invention has been described with reference to particular embodiments, workers skilled in the art will recognize that changes may be made in form and detail without departing from the spirit and scope of the invention.


Various modifications to the invention may be apparent to one of skill in the art upon reading this disclosure. For example, persons of ordinary skill in the relevant art will recognize that the various features described for the different embodiments of the invention can be suitably combined, un-combined, and re-combined with other features, alone, or in different combinations, within the spirit of the invention. Likewise, the various features described above should all be regarded as example embodiments, rather than limitations to the scope or spirit of the invention. Therefore, the above is not contemplated to limit the scope of the present invention.


For purposes of interpreting the claims for the present invention, it is expressly intended that the provisions of Section 112, sixth paragraph of 35 U.S.C. are not to be invoked unless the specific terms “means for” or “step for” are recited in a claim.

Claims
  • 1. A method for digitally generating and controlling a low frequency ultrasound used in a non-contact medical ultrasound therapy system, comprising: performing a power on self-test to an ultrasonic therapy system that includes a treatment wand comprising an ultrasonic transducer and a generator comprising an ultrasonic driver;performing a frequency sweep using a sine wave to determine a serial resonance frequency of the ultrasonic transducer by identifying a relative minimum impedance of the ultrasonic transducer;adjusting a digital frequency generator output frequency based on voltage vs. current phase angle to maintain a frequency lockup in a phase-continuous manner at the serial resonance frequency for exclusively non-contact low-load conditions and no-load conditions, wherein the system is driven at a constant current which maintains constant output displacement;and monitoring voltage and phase detection circuits of the ultrasound therapy system for phase difference, andwherein both a first microprocessor and a second microprocessor are configured to individually suspend operation of the ultrasound therapy system in a fault condition, wherein the fault condition corresponds to one or more of:a temperature of the generator,a temperature of the treatment wand,a temperature of the ultrasonic transducer, an output voltage of the ultrasonic transducer, or a communication failure between the first microprocessor and the second microprocessor.
RELATED APPLICATION

This application is a continuation of application Ser. No. 14/546,808 filed Nov. 18, 2014, which claims the benefit of U.S. Provisional Patent App. No. 61/909,086 filed Nov. 26, 2013, which is incorporated herein by reference in its entirety.

US Referenced Citations (308)
Number Name Date Kind
2534046 Mau Dec 1950 A
2889852 Dunlap Jun 1959 A
3207181 Willis Sep 1965 A
3243122 Snaper Mar 1966 A
3275059 McCullough Sep 1966 A
3392916 Engstrom Jul 1968 A
3433226 Boyd Mar 1969 A
3504887 Okerblom Apr 1970 A
3522801 Robinson Aug 1970 A
3561444 Boucher Feb 1971 A
3636947 Balamuth Jan 1972 A
3685634 Bergling Aug 1972 A
3685691 Ianelli Aug 1972 A
3685694 Ianelli Aug 1972 A
3765606 Moss Oct 1973 A
3860173 Sata Jan 1975 A
3874372 LeBon Apr 1975 A
3952918 Poitras Apr 1976 A
4052004 Martin Oct 1977 A
4085893 Durley Apr 1978 A
4153201 Berger May 1979 A
4185502 Frank Jan 1980 A
4192294 Vasilevsky Mar 1980 A
4251031 Martin Feb 1981 A
4271705 Crostack Jun 1981 A
4294407 Reichl Oct 1981 A
4301093 Eck Nov 1981 A
4301968 Berger Nov 1981 A
4309989 Fahim Jan 1982 A
4319155 Nakai Mar 1982 A
4331137 Sarui May 1982 A
4334531 Reichl Jun 1982 A
4352459 Berger Oct 1982 A
4414202 Anthony Nov 1983 A
4428531 Martin Jan 1984 A
4466571 Muhlbauer Aug 1984 A
4530360 Duarte Jul 1985 A
4541564 Berger Sep 1985 A
4551139 Plaas et al. Nov 1985 A
4582149 Slaughter, Jr. Apr 1986 A
4582654 Kamicky Apr 1986 A
4619400 Van Der Burgt Oct 1986 A
4642581 Erickson Feb 1987 A
4655393 Berger Apr 1987 A
4659014 Soth Apr 1987 A
4679551 Anthony Jul 1987 A
4726523 Kokubo Feb 1988 A
4726525 Yonekawa Feb 1988 A
4733820 Endo Mar 1988 A
4756478 Endo Jul 1988 A
4767402 Kost et al. Aug 1988 A
4783003 Hirabayashi Nov 1988 A
4790479 Matsumoto Dec 1988 A
4793339 Matsumoto Dec 1988 A
4815661 Anthony Mar 1989 A
4818697 Liboff Apr 1989 A
4850534 Takahashi et al. Jul 1989 A
4877989 Drews Oct 1989 A
4883045 Theisz Nov 1989 A
4905671 Senge Mar 1990 A
4930700 McKown Jun 1990 A
4941614 Ilott Jul 1990 A
4941618 Hildebrand Jul 1990 A
4961885 Avrahami Oct 1990 A
4982730 Lewis, Jr. Jan 1991 A
5002059 Crowley Mar 1991 A
5013241 Gutfeld May 1991 A
5040537 Katakura Aug 1991 A
5045066 Scheuble Sep 1991 A
5062795 Woog Nov 1991 A
5063922 Hakkinen Nov 1991 A
5067655 Farago Nov 1991 A
5076266 Babeav Dec 1991 A
5104042 McKown Apr 1992 A
5115805 Bommannan May 1992 A
5134993 van der L Aug 1992 A
5143588 Liboff Sep 1992 A
5152289 Viebach Oct 1992 A
5163433 Kagawa Nov 1992 A
5171215 Flanagan Dec 1992 A
5172692 Kulow et al. Dec 1992 A
5186162 Talish Feb 1993 A
5197946 Tachibana Mar 1993 A
5211160 Talish May 1993 A
5219401 Cathignol Jun 1993 A
5231975 Bommannan Aug 1993 A
5259384 Kaufman Nov 1993 A
5269291 Carter Dec 1993 A
5309898 Kaufman May 1994 A
5314441 Cusack May 1994 A
5315998 Tachibana May 1994 A
5316000 Chapelon May 1994 A
5318014 Carter Jun 1994 A
5323769 Bommannan Jun 1994 A
5324255 Passafaro Jun 1994 A
5345940 Seward Sep 1994 A
5347998 Hodson Sep 1994 A
5362309 Carter Nov 1994 A
5374266 Kataoka Dec 1994 A
5376855 Suganuma Dec 1994 A
5380411 Schlief Jan 1995 A
5386940 Berfield Feb 1995 A
5393296 Rattner Feb 1995 A
5431663 Carter Jul 1995 A
5437606 Tsukamoto Aug 1995 A
5456258 Kondo Oct 1995 A
5515841 Robertson May 1996 A
5515842 Ramseyer May 1996 A
5516043 Manna May 1996 A
5520166 Ritson May 1996 A
5520612 Winder May 1996 A
5523058 Umermura Jun 1996 A
5527350 Grove Jun 1996 A
5529572 Spector Jun 1996 A
5545124 Krause Aug 1996 A
5547459 Kaufman Aug 1996 A
5551416 Stimpson Sep 1996 A
5554172 Horner Sep 1996 A
5556372 Talish Sep 1996 A
5573497 Chapelon Nov 1996 A
5611993 Babaev Mar 1997 A
5616140 Prescott Apr 1997 A
5618275 Bock Apr 1997 A
5626554 Ryaby May 1997 A
5630828 Mawhirt May 1997 A
5643179 Fujimoto Jul 1997 A
5656016 Ogden Aug 1997 A
5658323 Miller Aug 1997 A
5664570 Bishop Sep 1997 A
5688224 Forkey Nov 1997 A
5699805 Seward Dec 1997 A
5702360 Dieras Dec 1997 A
5707402 Heim Jan 1998 A
5707403 Grove Jan 1998 A
5725494 Brisken Mar 1998 A
5730705 Talish Mar 1998 A
5735811 Brisken Apr 1998 A
5743863 Chapelon Apr 1998 A
5752924 Kaufman May 1998 A
5762616 Talish Jun 1998 A
5785972 Tyler Jul 1998 A
5807285 Vaitekunas Sep 1998 A
5835678 Li Nov 1998 A
5843139 Goedeke Dec 1998 A
5875976 Nelson Mar 1999 A
5879314 Peterson Mar 1999 A
5879364 Bromfield Mar 1999 A
5882302 Driscoll Mar 1999 A
5894841 Voges Apr 1999 A
5895362 Elstrom Apr 1999 A
5904659 Duarte May 1999 A
5947921 Johnson Sep 1999 A
5957882 Nita Sep 1999 A
5960792 Lloyd Oct 1999 A
5964223 Baran Oct 1999 A
5989245 Prescott Nov 1999 A
6001069 Tachibana Dec 1999 A
6007499 Martin Dec 1999 A
6014970 Irvi Jan 2000 A
6024718 Chen Feb 2000 A
6026808 Armer Feb 2000 A
6027495 Miller Feb 2000 A
6036661 Schwarze Mar 2000 A
6041253 Kost Mar 2000 A
6061597 Rieman May 2000 A
6076519 Johnson Jun 2000 A
6083159 Driscoll Jul 2000 A
6095141 Armer Aug 2000 A
6098620 Lloyd Aug 2000 A
6102298 Bush Aug 2000 A
6104952 Tu Aug 2000 A
6106547 Huei-Jung Aug 2000 A
6113558 Rosenschein Sep 2000 A
6113570 Siegel Sep 2000 A
RE36939 Tachibana Oct 2000 E
6139320 Hahn Oct 2000 A
6158388 Wenstrand Dec 2000 A
6158431 Poole Dec 2000 A
6161536 Redmon et al. Dec 2000 A
6176839 Deluis Jan 2001 B1
6186963 Schwarze Feb 2001 B1
6190315 Kost Feb 2001 B1
6190336 Duarte Feb 2001 B1
6206842 Tu Mar 2001 B1
6206843 Lger Mar 2001 B1
6231528 Kaufman May 2001 B1
6234990 Rowe May 2001 B1
6251099 Kollias Jun 2001 B1
6254294 Muhar Jul 2001 B1
6273864 Duarte Aug 2001 B1
6296630 Altman et al. Oct 2001 B1
6311573 Bhardwaj Nov 2001 B1
6314318 Petty Nov 2001 B1
6321109 Ben-Haim Nov 2001 B2
6322527 Talish Nov 2001 B1
6325769 Klopotek Dec 2001 B1
6392327 Lewis May 2002 B1
6450417 Gipson Sep 2002 B1
6458109 Henley Oct 2002 B1
6478754 Babaev Nov 2002 B1
6500133 Martin et al. Dec 2002 B2
6533484 Osei Mar 2003 B1
6533803 Babaev Mar 2003 B2
6559365 Wilfer May 2003 B2
6569099 Babaev May 2003 B1
6583071 Weidman Jun 2003 B1
6601581 Babaev Aug 2003 B1
6623444 Babaev Sep 2003 B2
6659365 Gipson Dec 2003 B2
6663554 Babaev Dec 2003 B2
6666431 McCusker Dec 2003 B2
6723064 Babaev Apr 2004 B2
6732744 Olshavsky May 2004 B2
6761729 Babaev Jul 2004 B2
6772967 Bontems Aug 2004 B1
6830556 Harmon Dec 2004 B2
6916296 Soring Jul 2005 B2
6960173 Babaev Nov 2005 B2
6964647 Babaev Nov 2005 B1
7025735 Soring Apr 2006 B2
7316664 Kadziauskas Jan 2008 B2
7431704 Babaev Oct 2008 B2
7572268 Babaev Aug 2009 B2
7662177 Babaev Feb 2010 B2
7713218 Babaev May 2010 B2
7729779 Babaev Jun 2010 B2
7753285 Babaev Jul 2010 B2
7780095 Babaev Aug 2010 B2
7785277 Babaev Aug 2010 B2
7785278 Babaev Aug 2010 B2
7830070 Babaev Nov 2010 B2
7901388 Babaev Mar 2011 B2
7914470 Babaev Mar 2011 B2
8074896 Ricciardi Dec 2011 B2
8491521 Peterson Jul 2013 B2
8647720 Staunton Feb 2014 B2
D733319 Somers et al. Jun 2015 S
D733321 Somers et al. Jun 2015 S
9365341 Bruna Jun 2016 B2
20020000763 Jones Jan 2002 A1
20020049462 Friedman Apr 2002 A1
20020049463 Friedman Apr 2002 A1
20020062093 Soring May 2002 A1
20020080206 Lin Jun 2002 A1
20020138036 Babaev Sep 2002 A1
20020150539 Unger Oct 2002 A1
20020156400 Babaev Oct 2002 A1
20020177846 Mulier et al. Nov 2002 A1
20030023193 Soring Jan 2003 A1
20030125660 Moutafis Jul 2003 A1
20030144627 Woehr Jul 2003 A1
20030153961 Babaev Aug 2003 A1
20030171701 Babaev Sep 2003 A1
20030195644 Borders Oct 2003 A1
20030216687 Hwang Nov 2003 A1
20030236560 Babaev Dec 2003 A1
20040015105 Ito Jan 2004 A1
20040028552 Bhardwaj Feb 2004 A1
20040030254 Babaev Feb 2004 A1
20040034982 Wieber Feb 2004 A1
20040055376 Thompson Mar 2004 A1
20040068297 Palti Apr 2004 A1
20040073175 Jacobsen Apr 2004 A1
20040076175 Patenaude Apr 2004 A1
20040091541 Unger May 2004 A1
20040162509 Sakurai Aug 2004 A1
20040186384 Babaev Sep 2004 A1
20040211260 Girmonsky Oct 2004 A1
20050075587 Vago Apr 2005 A1
20050075620 Iger Apr 2005 A1
20050086023 Ziegler Apr 2005 A1
20050203444 Schonenberger Sep 2005 A1
20060025716 Babaev Feb 2006 A1
20060058710 Babaev Mar 2006 A1
20070016110 Babaev et al. Jan 2007 A1
20070088245 Babaev et al. Apr 2007 A1
20070090205 Kunze Apr 2007 A1
20070299369 Babaev Dec 2007 A1
20080051693 Babaev Feb 2008 A1
20080110263 Klessel May 2008 A1
20080132888 Iida Jun 2008 A1
20080177221 Millerd Jul 2008 A1
20080183109 Babaev Jul 2008 A1
20080183200 Babaev Jul 2008 A1
20080214965 Peterson et al. Sep 2008 A1
20080234708 Houser Sep 2008 A1
20080243047 Babaev Oct 2008 A1
20080243048 Babaev Oct 2008 A1
20080306501 Babaev Dec 2008 A1
20090018491 Babaev Jan 2009 A1
20090018492 Babaev Jan 2009 A1
20090024076 Babaev Jan 2009 A1
20090043248 Peterson Feb 2009 A1
20090177122 Peterson Jul 2009 A1
20090177123 Peterson Jul 2009 A1
20090187136 Babaev Jul 2009 A1
20090200394 Babaev Aug 2009 A1
20090200396 Babaev Aug 2009 A1
20090222037 Babaev Sep 2009 A1
20090254005 Babaev Oct 2009 A1
20100022919 Peterson Jan 2010 A1
20100076349 Babaev Mar 2010 A1
20100249882 Houben Sep 2010 A1
20120010506 Ullrich Jan 2012 A1
20120223160 Goodwin Sep 2012 A1
20130053697 Holl Feb 2013 A1
20140276069 Amble Sep 2014 A1
20150148712 Loven May 2015 A1
Foreign Referenced Citations (34)
Number Date Country
2421798 Mar 2002 CA
2 359 426 Apr 2002 CA
2436812 Aug 2002 CA
1466445 Jan 2004 CN
0 202 844 Nov 1985 EP
0416106 Mar 1991 EP
0 437 155 Jul 1991 EP
0 657 226 Nov 1994 EP
0 619 104 Mar 2002 EP
1 199 047 Apr 2002 EP
0 1564009 Aug 2005 EP
2099710 Dec 1982 GB
2101500 Jan 1983 GB
3-73168 Mar 1991 JP
417844 Apr 1992 JP
9135908 May 1997 JP
2000237275 Sep 2000 JP
878268 Nov 1981 SU
910157 Mar 1982 SU
1106485 Oct 1982 SU
1176968 Sep 1985 SU
1237261 Jun 1986 SU
1827239 May 1990 SU
1704847 Jan 1992 SU
WO94-06380 Mar 1994 WO
WO 96-35383 Nov 1996 WO
W002-24150 Mar 2002 WO
WO 02-028350 Apr 2002 WO
W002-060525 Aug 2002 WO
WO02-095675 Nov 2002 WO
WO 2007-002598 Jan 2007 WO
WO 2009005980 Jan 2009 WO
WO 2009102976 Aug 2009 WO
WO 2016033041 Mar 2016 WO
Non-Patent Literature Citations (82)
Entry
U.S. Appl. No. 90/007,613, filed Sep. 25, 2000, Babaev.
Written Opinion for International Application No. PCT/US06/24833, dated Feb. 22, 2007, 5 pages.
Zharov et al, “Comparison Possibilities of Ultrasound and Its Combination with Laser in Surgery and Therapy”, pp. 331-339, In Biomedical Optoacoustics.
Asakawa, M. et al. , “WBN-Kob-Ht Rats Spontaneously Develop Dermatitis Under Conventional Conditions: Another Possible Model for Atopic Dermatitis,” Exp. Anim.,54(5): pp. 461-465 (2005).
Bisno, Alan.L., et al. , “Murine Model of Recurrent Group G Streptococcal Cellulitis: No Evidence of Proective Immunity,” Infection and Immunity, vol. 65 No. 12, pp. 4926-4930 © 1997.
Brooks, R.R., , “Canine Carrageenin-Induced Actue Paw Inflammation Model and its Response to Nonsteroidal Antiinflammatory Drugs,” J. Parrnacol Methods, 25, pp. 275-283 © 1991.
Chen, L. et al., The Disease Progression in the Keratin 14 IL-4-transgenic Mouse Model of Atopic Dermatitis Parallels the Up-regulation ofB Cell Activation Molecules, Proliferation and Surface and Serum lg;E, Clin, Exp. Immunolo, 142: 21-30 © 2005.
Chinese Office Action, dated May 22, 2009 for Chinese Application No. 2006800227860, 9 pages.
Department of Health & Human Services Letter dated Jun. 25, 2004, 3 pages.
Department of Health & Human Services Letter Dated May 17, 2005, 3 pages.
Zharov et al., Design and Application of Low-Frequency Ultrasound and Its Combination With Laser Radiation in Surgery and Therapy, Critical Reviews in Biomedical Engineering; No. 4, 2000, pp. 502-519.
Dong, Cheng, et al., “MAP Kinases in the Immune Response,” Annu. Rev. Immunol., 20: 55-72 © 2002.
Ennis, William J. et al. “Ultrasound Therapy for Recalcitrant Diabetic Foot Ulcers: Results of a Randomized, Double-Blind, Controlled, Multicenter Study”, Ostomy/Wound Management 2005; 51(8): pp. 24-39.
European Examination Report for European Application No. 01 973 554.8, dated Feb. 9, 2010, 3 pages.
European Examination Report for European Application No. 08 866 666.4, dated Mar. 22, 2011, 5 pages.
European Office Action from European Application No. EP01973544.8 dated Dec. 16, 2011, 4 pages.
European Search Report corresponding to European Application No. 01973544.8-2107—U.S. Pat. No. 130, 096, Applicant Advanced Medical Applications Inc., dated Sep. 13, 2004, 5 pages.
European Search Report, European Application No. 01973 544.8-2107—U.S. Pat. No. 130,096, dated Sep. 13, 2004, 5 pages.
European Search Report for European App. 0270923 5, dated Apr. 4, 2006.
European Supplementary Search Report corresponding to European Application No. 01973544, dated Sep. 1, 2004.
Examination Report, dated Dec. 5, 2007, for Indian App. 1078-MUMNP-2005.
Examination Report, dated Jul. 1, 2008, for European App. 02709235.2-2305, 4 pages.
Examination Report, dated Nov. 21, 2007, for European App. 02709235.2-2305, 4 pages.
Hammer, Robert E. et al. , “Spontaneous Inflammatory Disease in Transgenic Rats Expressing HLA-B27 and Human β2m: An Animal Model ofHLA-B27-Associated Human Disorders,” Cell, vol. 63, pp. 1099-1112, © 1990.
Haqqi, Tariq M., et al., “Restricted Heterogeneity in T-cell Antigen Receptor Vβ Gene Usage in the Lymph Nodes and Arthritic Joints of Mice,” Proc. Natl. Acad. Sci. USA, vol. 89: 1253-1255, Feb. 1992.
Hurvitz, A.l., “Animal Model of Human Disease, Pemphigus Vulgaris, Animal Model: Canine Pemphigus Vulgaris,” American Journal of Pathology, 98(3): 861-864 (1980).
International Search Report for EP 04749758.1-2319, dated Mar. 30, 2011, 5 pages.
International Search Report for PCT/US2004/010448, dated Nov. 10, 2004, 4 pages.
International Search Report for PCT/US01/31226, dated Sep. 11, 2002, 1 page.
International Search Report for PCT/US01/30096, dated Sep. 25, 2002, 1 page.
International Search Report for PCT/US02/02724, dated Dec. 11, 2002, 3 pages.
International Search Report for PCT/US06/24833, dated Feb. 22, 2007, 1 page.
International Search Report for PCT/US2007/026251, dated May 7, 2008, 2 pages.
International Search Report for PCT/US2008/000151, dated Apr. 21, 2008, 4 pages.
International Search Report for PCT/US95/14926, dated Feb. 27, 1996, 1 page.
Iraniha, Seed, et al. “Determination of Burn Depth With Noncontact Ultrasonography,” J. Burn Care Rehabil., 21:333-338, Jul./Aug. 2000.
Janeway, Charles A. et al., “Innate Immune Recognition”, Annual Review of Immunology 20: 197-216, © 2002.
Japanese Notification of Reasons for Rejection from Japanese Application No. 2008-518449 dated Jul. 29, 2011.
Japanese Office Action, dated Dec. 18, 2009 for Japanese Application No. 2002-528187.
Japanese Office Action, dated Jul. 29, 2010 for Japanese Application No. 2002-528187.
Bina, Joe et al. “Animal Models of Rheumatoid Arthritis,” Molecular Medicine Today, vol. 5, Aug. 1999, pp. 367-369.
Keffer, Jeanne , “Transgenic Mice Expressing Human Tumour Necrosis Factor: A Predictive Genetic Model of Arthritis,” The EMBO Journal, vol. 10, No. 13, pp. 4025-4031 (1991).
Liu, Z. et al., “Immunopathological Mechanisms of Acantholysis in Pemphigus Vulgaris: An Explanation by Ultrastructural Observations,” The Journal of Investigative Dermatology, © 2004.
Nishimuta, K. et al., “Effects of Metronidazole and Tinidazole Ointments on Models for Inflammatory Dermatitis in Mice,” Arch. Dermatol. Res., 294: 544-551 (2003).
Office Action and Machine Translation Summary of Office Action, dated Apr. 25, 2006, for Mexican App. PA-a-2003-002535, 3 pages.
Office Action and Machine Translation Summary of Office Action, dated Jul. 7, 2008, for Mexican App. PA-a-2003-002535, 3 pages.
Office Action dated Apr. 24, 2007, for Japanese App. No. 2002-560715 now JP-4,164,582, 3 pages.
Office Action, dated Apr. 20, 2007, for Chinese App. 01816263.0, 8 pages.
Office Action, dated Aug. 14, 2007, for Canadian App. 2,421,798, 3 pages.
Office Action, dated Aug. 5, 2009, for Canadian App. 2,421,798, 3 pages.
Office Action, dated Jan. 14, 2010, for Canadian App. 2,436,812, 3 pages.
Office Action, dated Jan. 18, 2008, for Chinese App. 01816263.0, 11 pages.
Office Action, dated May 18, 2006, for Canadian App. 2,421,798, 4 pages.
Office Action, dated May 3, 2006, for Canadian App. 2,43 6,812, 2 pages.
Office Action, dated Nov. 2, 2009, for Canadian App. 2,521,117, 3 pages.
Office Action, dated Nov. 5, 2009, for Japanese App. 2006-509708, 3 pages.
Office Action, dated Sep. 12, 2006, for Canadian App. 2,463,600, 3 pages.
Office Action, dated Sep. 26, 2007, for Canadian App. 2,521,117, 3 pages.
Pelletier, Jean-Pierre et al., “In vivo Suppression of Early Experimental Osteoarthritis by Interleukin-1 Receptor Antagonist Using Gene Therapy,” Arthritis & Rheumatism, vol. 40, No. 6, pp. 1012-1019, Jun. 1997.
Schon, Michael P. “Animal Models of Psoriasis—What Can We Learn from Them?”, The Journal of Investigative Dermatology, 112(4): 405-410 © 1999.
Trentham, David E., Autoimmunity to Type II Collagen: An Experimental Model of Arthritis, The Journal of Experimental Medicine, vol. 146, 1977.
Wooley, Paul H. , “Type II Collagen-Induced Arthritis in Mice, I. Major Histocompatibility Complex (I Region) Linkage and Antibody Correlates,” J. Exp. Med., vol. 154, pp. 688-700, Sep. 1981.
XP-002294548, Abstract corresponding to SU 914099.
Yamamoto, Toshiyuki, “Characteristics of Animal Models for Scleroderma,” Current Rheumatology Reviews, vol. 1, No. 1, pp. 101-109, (2005).
Application and File History for U.S. Appl. No. 09/704,099, filed Nov. 1, 2000, now U.S. Pat. No. 6,601,581, issued Aug. 5, 2003, Inventor: Eilaz Babaev.
Application and File History for U.S. Appl. No. 09/774,145, filed Jan. 30, 2001, now U.S. Pat. No. 6,960,173, issued Nov. 1, 2005, Inventor: Eilaz Babaev.
Application and File History for U.S. Appl. No. 09/840,416, filed Apr. 23, 2001, now U.S. Pat. No. 6,478,754, issued Nov. 12, 2002, Inventor: Eilaz Babaev.
Application and File History for U.S. Appl. No. 10/214,339, filed Aug. 7, 2002, now U.S. Pat. No. 6,663,554, issued Dec. 16, 2003, Inventor: Eilaz Babaev.
Application and File History for U.S. Appl. No. 09/669,312, filed Aug. 7, 2002, now U.S. Pat. No. 6,569,099, issued May 27, 2003, Inventor: Eilaz Babaev.
Application and File History for U.S. Appl. No. 10/409,272, filed Apr. 7, 2003, now U.S. Pat. No. 8,235,919, issued Aug. 7, 2012, Inventor: Eilaz Babaev.
Application and File History for U.S. Appl. No. 10/815,384, filed Apr. 1, 2004, now U.S. Pat. No. 7,914,470, issued Mar. 29, 2011, Inventor: Eilaz Babaev.
International Search Report, International Application No. PCT/US2014/066159, dated Mar. 24, 2015, 14 pages.
Examination Report for EP 04749758.1-2319, dated Apr. 30, 2010, 3 pages.
Clark, Richard A.F., The Molecular and Cellular Biology of Wound Repair, Second Edition, Wound Repair: Overview and General Considerations, Chapter 1, pp. 3-49.
International Preliminary Report on Patentability, International Application No. PCT/US2014/066159, dated Jun. 9, 2016, 10 pages.
European Search Report, Application No. 14865354.6, dated Jun. 28, 2017, 8 pages.
International Search Report and Written Opinion, International Application No. PCT/US17/44323, dated Oct. 25, 2017, 16 pages.
Amemark, Quick Reference Guide, Jun. 2015, 1 page.
Australian Examination Report, Application No. 2014355072, dated Aug. 29, 2018, 5 pages.
International Preliminary Report on Patentability, Application No. PCT/US2017/044323, dated Feb. 7, 2019, 10 pages.
European Examination Report, Patent Application No. 14865354.6, dated Jun. 18, 2019, 7 pages.
Australian Examination Report, Patent Application No. 2019219713, dated Mar. 19, 2020, 5 pages.
Related Publications (1)
Number Date Country
20200179725 A1 Jun 2020 US
Provisional Applications (1)
Number Date Country
61909086 Nov 2013 US
Continuations (1)
Number Date Country
Parent 14546808 Nov 2014 US
Child 16599389 US